module 205.2 en
TRANSCRIPT
![Page 1: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/1.jpg)
RETINOPATHY
![Page 2: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/2.jpg)
Objectives
![Page 3: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/3.jpg)
Eye disease in people with diabetes
![Page 4: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/4.jpg)
Transient changes in vision
![Page 5: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/5.jpg)
Retinopathy in people with diabetes
![Page 6: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/6.jpg)
When to screen for retinopathy
![Page 7: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/7.jpg)
Prevalence (%) ranges for retinopathy
![Page 8: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/8.jpg)
Risk factors
![Page 9: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/9.jpg)
Intensive therapy - type 1 diabetes
![Page 10: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/10.jpg)
Intensive therapy - type 2 diabetes
![Page 11: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/11.jpg)
Screening tests
![Page 12: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/12.jpg)
Diabetic retinopathy
![Page 13: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/13.jpg)
Normal retina
![Page 14: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/14.jpg)
Mild-moderate non-proliferative diabetic retinopathy (NPDR)
![Page 15: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/15.jpg)
Severe non-proliferative retinopathy
![Page 16: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/16.jpg)
Classifications
![Page 17: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/17.jpg)
Proliferative retinopathy
![Page 18: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/18.jpg)
Advanced proliferative retinopathy
![Page 19: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/19.jpg)
Vitreous haemorrhage
![Page 20: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/20.jpg)
Macular oedema
![Page 21: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/21.jpg)
Investigations
![Page 22: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/22.jpg)
Fluorescein angiogram
![Page 23: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/23.jpg)
Fluorescein leakage
![Page 24: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/24.jpg)
Treatment
![Page 25: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/25.jpg)
Pan-photocoagulation for proliferative retinopathy
![Page 26: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/26.jpg)
Pan-retinal laser photocoagulation
![Page 27: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/27.jpg)
Grid laser for macular oedema
![Page 28: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/28.jpg)
Laser therapy
![Page 29: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/29.jpg)
Recommendations
![Page 30: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/30.jpg)
Use of medical therapies
![Page 31: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/31.jpg)
Special populations: Pregnancy
![Page 32: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/32.jpg)
Special populations: The older person
![Page 33: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/33.jpg)
Summary
![Page 34: Module 205.2 en](https://reader036.vdocuments.mx/reader036/viewer/2022062523/58e49c511a28abf5428b53b3/html5/thumbnails/34.jpg)
References